Paula, the IPX066 open label extension that was cancelled was a follow-on to several earlier successful trials. The company had promised that participants in those earlier trials would be able to continue to use the test drug (IPX066) until it was approved for sale. The company changed their mind and cancelled the extension, thereby forcing the trial participants back to inferior drugs like sinemet. They didn't say why they changed their mind, but I suspect it was due to the fear that they had little to gain from the extension and possibly a lot to lose if abnormalities showed up in the extension.